Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

171 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95.
Simon A, Peoch M, Casassus P, Deconinck E, Colombat P, Desablens B, Tournilhac O, Eghbali H, Foussard C, Jaubert J, Vilque JP, Rossi JF, Lucas V, Delwail V, Thyss A, Maloisel F, Milpied N, le Gouill S, Lamy T, Gressin R. Simon A, et al. Among authors: casassus p. Br J Haematol. 2010 Oct;151(2):159-66. doi: 10.1111/j.1365-2141.2010.08329.x. Epub 2010 Aug 25. Br J Haematol. 2010. PMID: 20738307 Free article. Clinical Trial.
Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group.
Gressin R, Caulet-Maugendre S, Deconinck E, Tournilhac O, Gyan E, Moles MP, El Yamani A, Cornillon J, Rossi JF, Le Gouill S, Lepeu G, Damaj G, Celigny PS, Maisonneuve H, Corront B, Vilque JP, Casassus P, Lamy T, Colonna M, Colombat P; French GOELAMS Group. Gressin R, et al. Among authors: casassus p. Haematologica. 2010 Aug;95(8):1350-7. doi: 10.3324/haematol.2009.011759. Epub 2010 Mar 10. Haematologica. 2010. PMID: 20220059 Free PMC article. Clinical Trial.
Front-line high-dose chemotherapy with rituximab showed excellent long-term survival in adults with aggressive large b-cell lymphoma: final results of a Phase II GOELAMS Study.
Dilhuydy MS, Lamy T, Foussard C, Gressin R, Casassus P, Deconninck E, Le Maignan C, Damotte D, Milpied N; Groupe Ouest-Est des Leucémies et Autres Maladies du Sang (GOELAMS). Dilhuydy MS, et al. Among authors: casassus p. Biol Blood Marrow Transplant. 2010 May;16(5):672-7. doi: 10.1016/j.bbmt.2009.12.530. Epub 2010 Jan 4. Biol Blood Marrow Transplant. 2010. PMID: 20045738 Free article. Clinical Trial.
Twenty-year disease and treatment-associated mortality rates of patients with Hodgkin lymphoma of clinical stages IIIB and IV prospectively treated with 3-month anthracycline-based chemotherapy followed by extended high-dose radiation.
Sénécal D, Jais JP, Desablens B, Berthou C, Casassus P, Moles MP, Delwail V, Gastinne T, Colonna P, Andrieu JM. Sénécal D, et al. Among authors: casassus p. Cancer. 2008 Feb 15;112(4):846-55. doi: 10.1002/cncr.23247. Cancer. 2008. PMID: 18072259 Free article.
Intermediate stage Hodgkin lymphoma in partial remission after three or four courses of doxorubicin, bleomycin, vinblastine dacarbazine: no benefit of one course of intensive chemotherapy before irradiation.
Arakelyan N, Jais JP, Tomowiack C, Colombat P, Berthou C, Desablens B, Moles-Moreau MP, Gastinne T, Quittet P, Casassus P, Le Pourhiet-Le Mevel A, Ghandour C, Brière J, Colonna P, Andrieu JM. Arakelyan N, et al. Among authors: casassus p. Leuk Lymphoma. 2013 Jan;54(1):76-82. doi: 10.3109/10428194.2012.701737. Epub 2012 Jul 9. Leuk Lymphoma. 2013. PMID: 22680774 Clinical Trial.
Three cycles of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) or epirubicin, bleomycin, vinblastine, and methotrexate (EBVM) plus extended field radiation therapy in early and intermediate Hodgkin disease: 10-year results of a randomized trial.
le Maignan C, Desablens B, Delwail V, Dib M, Berthou C, Vigier M, Ghandour C, Atmani S, Casassus P, Maisonneuve H, Le Mevel A, Traulle C, Bernard M, Briere J, Colonna P, Andrieu JM. le Maignan C, et al. Among authors: casassus p. Blood. 2004 Jan 1;103(1):58-66. doi: 10.1182/blood-2003-05-1611. Epub 2003 Aug 7. Blood. 2004. PMID: 12907440 Free article. Clinical Trial.
Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.
Harousseau JL, Attal M, Avet-Loiseau H, Marit G, Caillot D, Mohty M, Lenain P, Hulin C, Facon T, Casassus P, Michallet M, Maisonneuve H, Benboubker L, Maloisel F, Petillon MO, Webb I, Mathiot C, Moreau P. Harousseau JL, et al. Among authors: casassus p. J Clin Oncol. 2010 Oct 20;28(30):4621-9. doi: 10.1200/JCO.2009.27.9158. Epub 2010 Sep 7. J Clin Oncol. 2010. PMID: 20823406 Clinical Trial.
Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation.
Feugier P, Labouyrie E, Djeridane M, Jenabian A, Dubruille V, Berthou C, Ghandour C, Desablens B, Chaït Y, Casassus P, Delwail V, Ifrah N, Le Mevel A, Lamy T, Brière J, Colonna P, Andrieu JM. Feugier P, et al. Among authors: casassus p. Blood. 2004 Nov 1;104(9):2675-81. doi: 10.1182/blood-2004-02-0567. Epub 2004 Jul 1. Blood. 2004. PMID: 15231567 Free article.
Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy.
Facon T, Mary JY, Pégourie B, Attal M, Renaud M, Sadoun A, Voillat L, Dorvaux V, Hulin C, Lepeu G, Harousseau JL, Eschard JP, Ferrant A, Blanc M, Maloisel F, Orfeuvre H, Rossi JF, Azaïs I, Monconduit M, Collet P, Anglaret B, Yakoub-Agha I, Wetterwald M, Eghbali H, Vekemans MC, Maisonneuve H, Troncy J, Grosbois B, Doyen C, Thyss A, Jaubert J, Casassus P, Thielemans B, Bataille R; Intergroupe Francophone du Myélome (IFM) group. Facon T, et al. Among authors: casassus p. Blood. 2006 Feb 15;107(4):1292-8. doi: 10.1182/blood-2005-04-1588. Epub 2005 Sep 20. Blood. 2006. PMID: 16174762 Free article. Clinical Trial.
Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome.
Yakoub-Agha I, Mary JY, Hulin C, Doyen C, Marit G, Benboubker L, Voillat L, Moreau P, Berthou C, Stoppa AM, Maloisel F, Rodon P, Dib M, Pegourie B, Casassus P, Slama B, Damaj G, Zerbib R, Harousseau JL, Mohty M, Facon T; Intergroupe Francophone du Myélome (IFM). Yakoub-Agha I, et al. Among authors: casassus p. Eur J Haematol. 2012 Mar;88(3):249-59. doi: 10.1111/j.1600-0609.2011.01729.x. Epub 2012 Jan 4. Eur J Haematol. 2012. PMID: 22023551 Clinical Trial.
171 results